CDK9-IN-2
规格
| Cas Number | 1263369-28-3(DMSO) |
| 规格或纯度 | 10mM in DMSO |
| 包装 | 1ml |
产品信息
| 品牌 | 阿拉丁 |
| 浓度 | 10mM in DMSO |
| 过滤标签 | CDK,Cell Cycle/DNA Damage,Compound libraries |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | CDK9-IN-2 是一种特殊的细胞周期蛋白依赖性激酶 9（CDK9）抑制剂，提取自专利 WO/2012131594A1，化合物 CDKI（8）在 H929 多发性骨髓瘤（MM）细胞系（72 小时）和 A2058 皮肤细胞系（72 小时）中的 IC 50 分别为 5 nM 和 7 nM。 |
| 英文描述 |
CDK9-IN-2 is a special cyclin-dependent kinase 9 ( CDK9 ) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC 50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. In Vitro CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic (PD) marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment and is further reduced after 16 hour exposure to CDK9-IN-2 (500 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. |